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Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumour associated with dismal prog-
nosis. To improve the outcome, early diagnostics is important. At present, classical HCC 
diagnostics is based on evaluation of risk factors, surveillance in cirrhotic patients, prefer-
ence for non-invasive diagnosis by computed tomography or magnetic resonance imag-
ing and biopsy confirmation in controversial cases. However, ambiguous radiological 
presentation, biopsy-related complications or insufficient representation of the pathol-
ogy in the tissue core are well-known problems. Panel assessment of microRNAs has 
diagnostic and prognostic value; thus, in future, microRNA-based liquid biopsy could 
partially reduce the need for core biopsies. Systemic inflammatory reaction (SIR), char-
acterised mainly by neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and 
Glasgow prognostic score, may have prognostic value and can be incorporated in criteria 
for certain treatment approaches, e.g., becoming an adjunct to Milan criteria. Thus, inno-
vations in HCC diagnostics are expected in the field of miRNA-based liquid biopsy for 
diagnosis/prognosis and SIR for prognosis/selection of treatment.
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1. Introduction
Hepatocellular carcinoma is one of the most aggressive human cancers. The total oncological 
mortality is decreasing in many developed countries, e.g., it has been reduced by 23% since 
1991 in the United States of America (USA). In contrast, death rate of HCC is increasing, along 
with the incidence of this tumour [1, 2]. Positive changes are expected due to risk factor eradica-
tion by vaccination against hepatitis B and improved treatment of chronic hepatitis C. The treat-
ment of HCC has also developed significantly, including radiofrequency ablation, transarterial 
chemoembolisation, liver resection and transplantation as well as molecular targeted treatment 
by sorafenib. However, SEER-based analysis has revealed that survival has improved in early 
but not in advanced cases [2]. Thus, timely diagnostics remain an important goal.
Most of the hepatocellular carcinoma cases develop on the background of liver cirrhosis or 
chronic inflammatory liver disease in precirrhotic stage, e.g. chronic viral hepatitis B or C, 
alcohol-induced or autoimmune liver disease or non-alcoholic steatohepatitis (NASH). This 
might facilitate the diagnostics by screening of the risk population. Nowadays, screening by 
ultrasonography and non-invasive radiological diagnosis by the means of computed tomog-
raphy or magnetic resonance imaging is the mainstay of HCC diagnostics. However, the 
radiological findings in early cases can be difficult to interpret. Biopsy is indicated in such 
controversial cases.
However, the biological course of HCC can result in diagnostic difficulties even in biopsy. 
HCC frequently develops in a dysplastic cirrhotic nodule. Such early HCC is typically well 
differentiated. Over time, it progresses to advanced dedifferentiated HCC. The resulting het-
erogeneity can lead to diagnostic problems and failures in biopsy due to sampling errors. 
For instance, if a small nodule seemed suspicious but not overtly malignant by radiological 
imaging, leading to biopsy, the differential diagnosis between dysplastic nodule and HCC 
will frequently imply the necessity to distinguish between premalignant process and well-
differentiated tumour, usually lacking marked cell atypia or clear-cut invasion. In addition, 
both processes can be adjacent in the tissues. Consequently, early diagnostics of HCC is not 
straightforward even in biopsy.
In addition, biopsy can cause complications, including arterial hypotension, bleeding, pneu-
mothorax, haemothorax, haemobilia, acute pancreatitis, visceral perforation, biliary fistulas, 
sepsis and needle breakage. Arterial hypotension is seen frequently (1.1–4.0%), mostly due to 
vasovagal reaction. In few cases, falling arterial blood pressure might indicate bleeding, if it is 
unusually severe. Bleeding can develop in the liver tissues or in the peritoneal cavity. It is seen 
in 4.5% of patients and is more frequent if INR is elevated: frequency of bleeding was 3.3% 
in patients having INR 1.3–1.5 and 7.1% among those who had INR > 1.5. Pneumothorax and 
haemothorax have been reported in 0.35 and 0.18% of patients, if the needle has accidentally 
passed through lung or diaphragmatic and intercostal blood vessels. Haemobilia has been 
described in 0.1% of patients and can induce acute pancreatitis via biliary obstruction. The 
frequency of visceral perforation, biliary fistulas, sepsis and needle breakage is 0.01% each. In 
addition, biopsy can result in pain, experienced in up to 84% of patients. In 40% of cases, pain 
lasts for 24 hours. It is attributable to skin and liver capsule damage, viscerosomatic irradiation 
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(to shoulder) or complications that lead to peritoneal irritation (bleeding, bile accumulation in 
the peritoneum perforation of the internal organs). Few death cases have been reported after 
liver biopsy: 0.01–0.1% of patients [3].
Non-invasive means of HCC diagnostics would be beneficial. Two promising pathways 
include so-called liquid biopsy by microRNA analysis in blood and assessment of tumour-
induced systemic inflammatory reaction (SIR). MicroRNA spectrum might have diagnostic 
and prognostic value. Regarding SIR, prognostic aspects have been studied and appear as 
promising adjunct how to select patients for treatment.
2. miRNAs in the diagnostics of hepatocellular carcinoma
MicroRNAs (miRNAs) are small, double-stranded, non-coding RNA molecules consisting of 
approximately 22 nucleotides. MiRNAs regulate gene expression at the post-transcriptional 
level [4, 5] acting as large-scale molecular switches. MiRNAs are found not only in cells but 
also in body fluids. Due to the stable and relatively simple structure, these molecules are good 
biomarkers for diagnostic and prognostic evaluation complying with the idea of so-called 
liquid biopsy—a patient-friendly blood test bringing the same information as a biopsy. In 
order to increase the diagnostic value of such tests, panels of miRNAs have been advocated. 
However, the biological course of HCC cause a possible pitfall in the elaboration of such 
diagnostic tests: as HCC mainly arise on the background of liver cirrhosis, inflammatory or 
metabolic liver diseases, these preceding pathologies can also alter the levels of miRNAs.
MiRNA-122 is attractive for its wide expression in liver tissues suggesting significant role in 
liver functions. MiRNA-122 is upregulated in serum of HCC patients and downregulated in 
HCC tissues suggesting specific excretion of miRNA-122 in blood by HCC. Although miRNA-
122 shows high specificity and sensitivity for HCC in comparison with healthy controls (83.3 
and 81.6%, respectively), levels of miRNA-122 change in other liver pathologies as well, limit-
ing the diagnostic application [6].
Comparing HCC patients with those having hepatitis B or liver cirrhosis, serum levels of exo-
somal miRNA-18a, miRNA-221, miRNA-222 and miRNA-224 were increased, while miRNA-
101, miRNA-106b, miRNA-122 and miRNA-195 were decreased. MiRNA-16 was decreased 
in HCC, and the levels significantly differed from those found in hepatitis C virus (HCV) 
infection because chronic viral hepatitis C and non-alcoholic fatty liver disease are character-
ised by the contrary changes—increase in miRNA-16. MiRNA-21 is characterised by positive 
characteristics in meta-analysis showing specificity and sensitivity for HCC diagnosis of 84.8 
and 81.2%, respectively. The changes of miRNA-21 serum levels in HCC patients significantly 
differ from cases of chronic hepatitis; however, other malignant tumours can also yield higher 
serum concentration of miRNA-21 [7].
Several panels of miRNAs have been recommended. Exploring nine serum miRNAs (miRNA-
21, miRNA-30c, miRNA-93, miRNA-122, miRNA-125b, miRNA-126, miRNA-130a, miRNA-
193b and miRNA-222) in HCC and chronic viral hepatitis C patients, nine markers were 
decreased in chronic hepatitis C versus healthy controls, while seven markers (miRNA-21, 
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miRNA-30c, miRNA-93, miRNA-122, miRNA-125b, miRNA-130a and miRNA-222) were 
significantly (p < 0.05) decreased in HCC versus chronic viral hepatitis C patients and four 
(miRNA-93, miRNA-122, miRNA-125b and miRNA-130a) in HCC versus non-HCC patients 
[8]. Panel of three miRNAs (upregulated miRNA-92a-3p, downregulated miRNA-3126-5p 
and upregulated miRNA-107) could discriminate HCC from healthy controls [9] Evaluating 
serum levels of 13 miRNAs in HCV-associated chronic hepatitis, liver cirrhosis and HCC ver-
sus healthy controls, panel of three miRNAs (miRNA-122, miRNA-885-5p and miRNA-29b) 
in association with serum alpha-fetoprotein (AFP) level could identify HCC versus healthy 
persons, while four miRNAs (miRNA-122, miRNA-885-5p, miRNA-221 and miRNA-22) 
and AFP were recommended for HCC diagnostics in liver cirrhosis and two (miRNA-22, 
miRNA-199a-3p) along with AFP—in chronic hepatitis [10]. In another study of HCV-infected 
patients including cases of HCV-related chronic hepatitis, liver cirrhosis and HCC, serum lev-
els of miRNA-126, miRNA-129, miRNA-155, miRNA-203 and miRNA-223 were significantly 
decreased in HCC versus non-HCC patients [11]. Panel of eight miRNAs was assessed in hep-
atitis B virus-infected patients diagnosed with HCC or liver cirrhosis as well as in healthy 
controls. The levels of hsa-miRNA-206, hsa-miRNA-141-3p, hsa-miRNA-433-3p and hsa-
miRNA-1228-5p were significantly increased in HCC versus control group comprising both 
healthy and cirrhosis patients, while hsa-miRNA-199a-5p, hsa-miRNA-122-5p, hsa-miRNA-
192-5p and hsa-miRNA-26a-5p were downregulated [4].
In addition to the diagnostic role, miRNAs have been evaluated in the prognostic aspect. The 
influence of miRNAs upon HCC stem cells has been exploited. It has also been suggested that 
miRNAs could become treatment targets [12].
3. Systemic inflammatory response
Many tumours, including hepatocellular carcinoma, evoke systemic inflammatory reac-
tion (SIR). In the recent years, cancer-induced SIR has become an attractive research area 
as changes in blood cell counts or ratios or blood levels of certain proteins are associated 
with the biological potential, course and treatment response in many malignant tumours. 
Although complex pathogenesis lies behind these changes, SIR can be evaluated by simple, 
widely available and economically feasible blood tests.
SIR in cancer patients develops through local and central mechanisms. Locally, the inva-
sive growth of malignant tumour injures surrounding parenchyma, connective tissues and 
endothelium. The tissue damage leads to inflammation necessitating supply of inflamma-
tory cells from the bone marrow through the circulation. The production of acute phase 
proteins becomes upregulated as well. Endothelial injury activates platelets; indeed, the asso-
ciation between hypercoagulation and advanced cancers is classical. Tumour necrosis and 
hypoxia are additional causes of local inflammatory response. Cancer can also evoke immune 
response manifesting by local cellular reactions. In turn, the inflammation can have both 
tumour-enhancing and tumour-suppressing outcomes. The released cytokines and transcrip-
tion factors can upregulate the proliferation of malignant cells. Release of metalloproteinases 
and other enzymes can promote tissue degradation facilitating invasion. Angiogenesis can be 
upregulated as well. The immune system, in turn, can limit growth of the tumour.
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The systemic effects of cancer include alterations in bone marrow function, especially myelo-
poiesis. Besides the increased production and release of leukocytes, immature myeloid cells, 
including the precursors of granulocytes and monocytes, are retained in early stages of differ-
entiation. Immature myeloid cells can act as immune suppressors and generate pre-metastatic 
niches, among other pathogenetic processes [13]. Thus, it has even been stated that cancer is 
an inflammatory disease [14]. Further, neutrophils can form neutrophil extracellular traps 
developed from externalised DNA network. These nets are bidirectionally associated with 
platelet activation and can contribute to cancer progression via several mechanisms; there-
fore, neutrophil extracellular traps also represent an attractive treatment target [15].
Cancer-related SIR involves cells of innate and adaptive immunity as well as soluble factors. 
Macrophages are recruited in tumour by hypoxia and tumour-released molecular agents 
including growth factors and cytokines [16]. Macrophage phenotype switch from tumour-
suppressing classical M1 to tumour-promoting M2 subtype promotes angiogenesis and immu-
nosuppression. Platelet activation contributes to cancer progression and patient mortality [15]. 
Neutrophils are locally recruited in the cancer via chemokine signalling. Neutrophil activation 
can contribute to angiogenesis and increased blood vessel permeability locally and metastatic 
spread systemically. In addition, immature myeloid cells and neutrophil extracellular traps 
might have tumour-promoting activity. These molecular events also highlight the associa-
tion between infection or surgery-induced inflammation [17] and cancer relapse or metastatic 
spread. Thus, innate immunity is generally thought to act as tumour enhancers. In contrast, 
lymphocytes representing the adaptive immunity are considered to have tumour-suppressing 
effects [16], although contrary effects have been ascribed to certain subpopulations [18].
HCC can be considered a classical inflammation-induced cancer, as its most common risk 
factors are hepatitis B and hepatitis C virus infections. Inflammation is also present in liver 
tissues in patients affected by alcohol-induced hepatitis or NASH. Thus, SIR is not expected 
to have diagnostic value. Indeed, SIR parameters change before the tumour develops, e.g., 
increased NLR has been observed in chronic viral hepatitis C [19]. NLR is an independent 
prognostic factor in liver cirrhosis [20].
Wide variety of inflammation-based markers could be used as indicators of HCC prognosis, 
tumour recurrence and response to specific treatment. In particular, neutrophil, lymphocyte 
and platelet counts as well as C-reactive protein and albumin and their combinations, neutro-
phil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and Glasgow prognostic 
score (GPS) have prognostic value.
3.1. Neutrophil-to-lymphocyte ratio in HCC
Neutrophil-to-lymphocyte ratio is the most extensively evaluated parameter of SIR in 
HCC. NLR, calculated as the ratio between count of neutrophils and lymphocytes in blood, 
seems to reflect the intensity of systemic pro- and anti-tumour reaction. NLR has shown prog-
nostic importance in surgically treated HCC cases, including early stage tumours; in liver 
transplantation; sorafenib treatment and different ablation techniques.
Several meta-analyses have been devoted to NLR in HCC patients. Thus, baseline NLR was 
associated with overall survival and recurrence-free survival, while post-treatment NLR was 
significantly associated with overall survival [21]. In meta-analysis of NLR in HCC patients 
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treated by liver transplantation, significant association with overall and recurrence-free sur-
vival was found [22]. In an early study, NLR was already confirmed as a prognostic factor 
in HCC. NLR was associated with overall and disease-free survival both generally and after 
different treatment approaches [23].
3.2. Neutrophil-to-lymphocyte ratio in surgically treated HCC
In HCC patients subjected to curative resection, several research groups have identified high 
NLR as an independent, significant predictive factor, associated with worse overall survival 
[24–27], shorter recurrence-free survival [24, 25, 28] and higher frequency of recurrence [29].
The studies show some variability in design, group size and cut-off level. However, the 
reported differences in survival are not only statistically significant but also biologically 
important. In 672 HCC patients treated by surgical resection, the recurrence rate within 1, 3 
and 5 years was 77.4, 55.2 and 44.8% in those having low NLR (≤2.5), while the corresponding 
recurrence rates were 64.1, 45.2 and 35.5% (p = 0.016) in high NLR group [29]. In 303 patients 
who underwent surgical liver resection for HCC, high NLR (>2.0, based on ROC-detected 
cut-off) was significantly associated both with shorter recurrence-free and overall survival 
(both p < 0.001), but multivariate analysis confirmed it as an independent prognostic factor 
only for overall survival (hazard ratio (HR) 1.724; 95% confidence interval (CI): 1.241–2.394; 
p = 0.001). Huang et al. evaluated 1659 HCC patients, stratifying them by NLR quartiles. The 
5-year overall survival rate was 60% in the lowest quartile contrasting with 27% in the highest 
quartile. NLR was associated by HR of mortality 1.031; 95% CI: 1.002–1.060; p = 0.033 [30]. In 
a large Japanese study, enrolling 958 patients who underwent hepatectomy, the 5-year sur-
vival rate was 72.9% in low NLR (<2.81) group versus 51.5% in patients with high NLR [24]. 
In another 256 Japanese patients, NLR was confirmed by multivariate analysis as an indepen-
dent prognostic factor both for overall and recurrence-free interval. The respective hazard 
ratios were 2.59; 95% CI: 1.56–4.31; p < 0.001 and 2.11; 95% CI = 1.44–3.11; p < 0.001 [25]. In a 
smaller study of 113 patients, the recurrence-free survival was 42.4 months in patients having 
NLR < 3 but 7.9 months in those having NLR ≥ 3.0. The respective HR was 2.58; p = 0.002 [28].
The findings in Western patients have been less positive. In the largest Western series com-
prising 370 patients, treated in Memorial Sloan Kettering Cancer Center in New York, USA, 
PLR, but not NLR, was independently associated with worse recurrence-free survival and 
overall survival [31].
NLR retains prognostic value in several subgroups of surgically treated patients, including 
early cases. By multivariate analysis, preoperative NLR (at cut-off 2.8) was the strongest inde-
pendent prognostic factor for overall survival after liver resection with curative intent for 
TNM stage I HCC. The HR was 2.69; 95% CI: 1.57–4.59; p < 0.001. The 5-year survival in high 
versus low NLR group was 45.0 versus 76.4%; p < 0.001. Interestingly, the association with 
survival in stage II or III was not significant, reflected by p = 0.283 and p = 0.155. In stage I 
patients, high NLR predicted more frequent extrahepatic recurrence (p = 0.006). As growth of 
HCC is associated with grade progression, these results suggest that NLR reflects the biologi-
cal potential of HCC [32]. In Chinese cohort of 222 patients, preoperative NLR, using cut-off at 
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2.1, predicted overall survival in solitary small (≤5 cm) HCC after surgical resection and could 
discriminate outcome in patients having AFP levels not exceeding 400 ng/mL [33]. Further, 
in a large study of 963 HCC patients treated by potentially curative surgical resection, high 
NLR (>2.81) was an independent risk factor for overall and recurrence-free survival (both p <   
0.001) in the general group as well as in early or intermediate stage HCC: Barcelona Clinic 
Liver Cancer (BCLC) stages 0/A or B (both p  <  0.05) while no association was found in stage C 
[34]. NLR was also not associated with early (<1 year) mortality from cancer recurrence after 
liver resection for huge (at least 10 cm in diameter) HCC in 166 patients [35]. NLR was an 
independent factor that predicted (p = 0.029) early recurrence after curative resection of HCC 
presenting as a single focus in 193 Japanese patients [36]. However, contrary results have been 
reported as well, e.g., NLR had no prognostic significance in early HCC (BCLC stage 0/A) 
treated by surgical resection in 324 patients [37].
Somewhat contrasting data are reported regarding NLR in surgically treated patients with 
more advanced HCC. Although limited significance of NLR was previously noted in high-
stage or large HCC, some authors have found significant role of NLR in advanced cases. Thus, 
in 81 hepatectomy-treated HCC patients with portal or hepatic vein tumour thrombosis, high 
NLR (defined as >2.9) was an independent prognostic factor for worse overall survival, char-
acterised by HR 1.866; 95% CI: 1.048–3.322; p = 0.034. Significant association with recurrence-
free interval was found as well. The overall survival in high versus low NLR groups was 
6.2 months versus 15.7 months; p = 0.007, while the recurrence-free survival was 2.2 versus 
3.7 months; p = 0.039 [38].
Not only baseline NLR but also the dynamic changes of NLR were found to be important. 
In 189 patients treated by curative resection for small HCC, the temporal change of NLR 
was an independent prognostic factor for overall (HR 2.637; 95% CI: 1.356–5.128; p = 0.004) 
and recurrence-free (HR 2.372; 95% CI: 1.563–3.601; p < 0.001) survival. The 1-, 3- and 5-year 
survival was 92.7, 70.0 and 53.0% in patients experiencing NLR increase versus 96.2, 87.5 and 
75.9% in those with decreasing NLR (p = 0.003). High preoperative or postoperative NLR 
had lower prognostic value in this study [39]. Paralleling observations have been reported 
by Hung et al., studying patients with HCC recurrence after liver resection. The 5-year post 
recurrence survival was better (45.9%) in those continuously having NLR ≤ 2.5. Patients who 
had low NLR (≤2.5) at resection but high level (>2.5) at recurrence had 5-year survival of only 
24.6%; the difference was significant as reflected by p = 0.013 [29].
3.3. Neutrophil-to-lymphocyte ratio in patients receiving transplantation for HCC
Different aspects of NLR have been evaluated in HCC patients subjected to liver transplanta-
tion, including transplantation from living donor. The prognostic value of NLR was revealed 
already in the early studies. Thus, NLR (applying the cut-off level at 5.0) was an independent 
predictor of overall and recurrence-free survival in 219 Italian patients after liver transplanta-
tion for HCC [40].
By univariate analysis, preoperative NLR was significantly associated by disease-free survival 
and overall survival in HCC patients after liver transplantation. The 1-, 3- and 5-year overall 
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survival rate in high versus low NLR group was 81.3, 56.7 and 51.0 versus 90.9, 74.2 and 66.8% 
(p = 0.041). Similarly, the 1-, 3- and 5-year recurrence-free survival rate in high versus low NLR 
group was 65.3, 48.5 and 39.4 versus 80.0, 68.0 and 65.2%. The difference was also significant 
as reflected by p = 0.013 [41]. Further, NLR was an independent prognostic factor for overall 
and recurrence-free survival after liver transplantation for HCC as was shown by multivariate 
analysis of 160 Western patients [42]. NLR was proved to be an independent risk factor for 
overall survival (p < 0.001) and recurrence-free survival (p = 0.003) in 248 male patients treated 
by liver transplantation [43]. Harimoto et al. reported on 213 patients receiving living donor 
liver transplantation for HCC. High preoperative NLR ≥ 2.66 was an independent predictor 
of recurrence [44].
NLR can be used in prognostic models to identify patients who exceed Milan criteria but still 
have good overall and tumour-free survival. In study reported by Wang et al., male patients 
were enrolled and thus the proposed models were verified in males only [43]. Combination 
of NLR and Hangzhou criteria has been suggested to identify patients who can be success-
fully treated by liver transplantation [45]. NLR has been included in the MORAL scores to 
predict recurrence after liver transplantation, and these scores were superior to Milan criteria 
[46]. Complex evaluation of NLR along with fibrinogen increases the prognostic accuracy in 
order to predict disease-free survival and overall survival in HCC patients treated by liver 
transplantation [41]. Pretransplantation NLR along with levels of C-reactive protein has been 
combined with Milan criteria to develop new selection criteria for living donor liver trans-
plantation beyond Milan criteria [47].
However, contrasting findings have been published as well. Thus, NLR did not predict post-
transplantation recurrence or worse overall survival in 150 patients within Milan criteria [48]. 
Limited prognostic impact of NLR was found in 124 patients who underwent living donor 
liver transplantation [49]. In Western patients, NLR was not predictive of treatment success 
regarding liver transplantation or other tested approaches (hepatectomy, transarterial chemo-
embolisation). Although the group was quite small (75), Child-Pugh and Model for End Stage 
Liver Disease (MELD) scores were informative [50].
3.4. Neutrophil-to-lymphocyte ratio in sorafenib-treated HCC patients
In patients with unresectable HCC, treated by multikinase inhibitor sorafenib, high NLR 
(>3.1) was a significant independent prognostic factor, associated with worse overall survival. 
Better treatment response was observed in patients with low NLR [51]. The findings were 
confirmed by another study, reporting on 442 sorafenib-treated patients (Japan, Italy and 
United Kingdom) with advanced HCC. High NLR again was an independent prognostic fac-
tor, predicting shorter survival with HR 1.218; 95% CI: 1.108–1.322; p < 0.0001 [52].
Regarding combined approach, high pre-treatment NLR (>3.0) was an independent predic-
tor of worse overall survival in 40 patients with unresectable HCC treated by transcatheter 
arterial embolisation and sorafenib. The median survival in high versus low NLR group was 
14 months (95% CI = 10.1–17.9) versus 26 months (95% CI = 17.4–34.6). The difference was 
significant (p = 0.001) and biologically remarkable [53]. Other researchers have also confirmed 
that NLR was independent predictor of overall survival in patients with advanced HCC 
treated by sorafenib [54].
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3.5. Neutrophil-to-lymphocyte ratio in HCC patients undergoing tumour ablation
NLR has been investigated in regard to different embolisation and ablation techniques. High 
NLR (>3) predicted significantly worse treatment results (p = 0.014) and early disease pro-
gression (p < 0.0001) in 86 treatment-naive patients subjected to arterial chemoembolisation 
or radioembolisation [55]. Elevated pre-treatment NLR (>1.85) was associated with overall 
survival and disease-free survival in 178 HCC patients subjected to transcatheter arterial che-
moembolisation (TACE). The median survival in high versus low NLR group was 8 versus 
17.5 months. The 1-, 3- and 5-year overall survival rates in these groups were 42.1, 19.6 and 9.5 
versus 57.3, 44.1 and 27.2%, respectively (p < 0.001). Differences in disease-free survival were 
significant as well (p < 0.001). Multivariate analysis confirmed NLR as a significant (p = 0.04), 
independent prognostic factor for survival after TACE [56].
In patients with advanced HCC treated by hepatic arterial infusion chemotherapy, high NLR 
was a significant predictor of lower response rate, worse progression-free and overall survival 
[57]. Baseline NLR was a significant predictor of treatment response and progression-free sur-
vival after hepatic arterial infusion chemotherapy for advanced HCC [58]. In patients receiv-
ing hepatic arterial infusion chemotherapy by cisplatin and fluorouracil, response rate and 
overall survival were associated with NLR [59].
Dynamic changes of NLR had independent prognostic significance (p = 0.035) in HCC with 
portal vein tumour thrombosis treated by microwave ablation after transarterial chemo-
embolisation [60]. In 506 patients treated by thermal ablation of recurrent HCC, high pre-
treatment NLR (≥2.14) was a prognostic factor for recurrence-free survival, confirmed by 
Cox multiple regression analysis. The 1- and 3-year recurrence rates in high versus low NLR 
groups were 57.9 and 82.5 versus 20.7 and 31.6%. The difference was statistically significant, 
confirmed by p < 0.001 [61].
Pre-treatment NLR was associated with worse overall survival in early HCC after radiofre-
quency ablation. Post-treatment NLR was associated both with worse overall survival and 
recurrence in early HCC after radiofrequency ablation [62]. Similarly, NLR dynamics, but not 
pre-treatment NLR, was an independent prognostic factor for overall survival and recurrence-
free survival in patients with small HCC treated by radiofrequency ablation [63]. In patients 
treated by radiofrequency ablation for HCC, post-treatment NLR was associated with recur-
rence and survival. Pre-treatment NLR was associated with recurrence only in patients who 
had HBV infection and HCC but not in those who developed HCC in association with HCV 
infection [64]. In unresectable HCC treated by radioembolisation, elevated NLR was an inde-
pendent predictor of worse survival [65].
3.6. Neutrophil-to-lymphocyte ratio and tumour characteristics
NLR has been mostly assessed in correlation with survival or treatment response. However, 
some observations are reported on the association between systemic inflammatory response 
and tumour morphology in gross and microscopic level. Thus, high NLR is observed in 
patients having larger tumours, multiple HCC foci, higher grade of HCC and vascular inva-
sion [29]. In few studies, the infiltration of neutrophils and macrophages in liver tumours has 
been assessed. Peritumoural tissues are characterised by higher ratio between neutrophils 
Innovative Blood Tests for Hepatocellular Carcinoma: Liquid Biopsy and Evaluation of Systemic…
http://dx.doi.org/10.5772/intechopen.76599
55
and T lymphocytes, and higher ratio also correlates with lower overall survival. The combi-
nation of these findings suggests that neutrophils might facilitate tumour progression. They 
suppress adaptive immunity by death ligand expression [66]. Correlation between NLR and 
PD-L1 expression in the centre of tumour but not peritumoural tissues has been described 
[67]. High NLR was associated with CD163-positive tumour-associated macrophages [24]. 
High NLR was associated with higher peritumoural but not intratumoural CD163 and IL-17-
expressing cells [68].
3.7. Platelet-to-lymphocyte ratio in HCC patients
Platelet-to-lymphocyte ratio (PLR) is another frequently assessed estimate of SIR, although 
fewer publications have been devoted to PLR than to NLR. Nevertheless, prognostic role of 
PLR has been evaluated in different aspects of HCC patient treatment, including surgery [31, 
69, 70], transplantation, sorafenib treatment, TACE and ablation techniques.
In the largest Western series enrolling 370 HCC patients, treated by surgical resection, higher 
preoperative PLR was identified as an independent risk factor of worse overall survival and 
recurrence-free survival [31]. Other research groups have confirmed the association between 
PLR and prognosis. Higher preoperative PLR is an independent predictor of worse overall 
survival in HCC patients undergoing curative liver resection [69, 70] as was shown in two 
large Eastern cohorts comprising 778 [70] and 1804 [69] patients, respectively. The significant 
association with overall survival (p < 0.001) was retained in specific subgroups, e.g., patients 
having cirrhosis or being positive for HbsAg [70]. In some studies, the associations between 
PLR and prognosis were statistically significant but not independent. Thus, PLR was signifi-
cantly associated with disease-free and overall survival in 332 HCC patients after hepatec-
tomy [71]. The association between higher PLR and shorter recurrence-free survival in HCC 
patients undergoing curative liver resection was statistically significant but not independent 
[70]. Finally, no association has been found in some studies. Hence, in 113 HCC patients 
undergoing curative resection, PLR was not confirmed as a significant prognostic factor for 
recurrence-free survival. NLR was found to be superior in this study [28].
PLR has been analysed in the context of liver transplantation. Already in early studies, statis-
tically significant association was found between pretransplantation PLR and cancer recur-
rence after liver transplantation. In 146 patients, the recurrence-free survival was 80.7 versus 
91.6%; the difference was statistically significant as confirmed by p = 0.02 [72].
In 122 Chinese patients undergoing transarterial chemoembolisation (TACE) for HBV-related 
HCC, high pre-treatment PLR (≥96.13) was an independent, statistically significant (p = 0.001) 
factor that predicted worse survival [73].
In 414 patients affected by recurrent HCC and treated by thermal ablation, high pre-treatment 
PLR (≥87.87) was associated with higher risk of recurrence and worse recurrence-free sur-
vival. The 1- and 3-year recurrence rates in high versus low PLR groups were 56.0 and 79.5 
versus 39.9 and 54.8%; p < 0.05 [74].
Regarding sorafenib-treated cases, PLR has not shown prognostic value in patients receiving 
sorafenib for advanced HCC. Although the negative result could be attributed to the small 
group size (16 patients), significant association with NLR was still confirmed [75].
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Several meta-analyses have recently been carried out to evaluate PLR in hepatocellular carci-
noma. Significant association between higher PLR and increased risk of death was reported 
by Hu and Yu, reporting odds ratio for death 1.59; 95% CI: 1.15–2.20 on the basis of meta-
analysis of six studies with 1446 HCC patients [76]. The association between high PLR and 
worse overall survival was confirmed by Ma et al., Song et al., and Zhao et al. [77–79]. In a 
meta-analysis of nine studies including 2017 patients, high PLR was associated with poor 
overall survival (HR 1.63; 95% CI: 1.42–1.88; p < 0.001) as reported by Ma et al. [77]. Evaluating 
2507 patients in 11 studies, high PLR was significantly associated with worse overall survival, 
as reflected by hazard ratio HR = 1.78; 95% CI: 1.36–2.34; p < 0.001 [78]. In a meta-analysis of 
10 studies including 2315 patients, high PLR was associated with the HR for worse overall 
survival of 1.60; 95% CI: 1.23–2.08; p = 0.0005 [79].
Controversial findings are reported regarding PLR and recurrence-free survival. The associa-
tion has been confirmed by some research groups [77, 78] but denied by others. In a meta-anal-
ysis of nine studies including 2017 patients, high PLR was significantly (p < 0.001) associated 
with poor recurrence-free survival: HR = 1.32; 95% CI: 1.15–1.52. In a meta-analysis of 11 studies 
comprising 2507 patients, elevated PLR was significantly associated with worse recurrence-free 
survival, as reflected by hazard ratio HR = 1.82; 95% CI: 1.56–2.13; p < 0.001. In contrast, by meta-
analysis of 2315 patients in 10 studies, high PLR was not significantly associated with worse 
recurrence-free survival as the HR was 1.21; 95% CI: 0.87–1.67; p = 0.26 [79].
High PLR also showed correlation with high tumour size exceeding 3 cm, TNM stage, lymph 
node metastases and distant metastases [78]. The findings regarding vascular invasion are 
controversial again, as the association is confirmed in some studies [78] but not others [77]. No 
association between PLR and tumour multifocality and higher grade has been confirmed [77].
3.8. Glasgow prognostic score in hepatocellular carcinoma
The prognosis and treatment options of HCC patients depend not only on tumour progres-
sion but also on the extent of liver dysfunction. As a consequence, several staging systems 
have been proposed to predict prognosis for HCC, including Glasgow prognostic score (GPS), 
based on the levels of C-reactive protein and albumin (Table 1). GPS in HCC patients with 
hepatocellular carcinoma is an independent prognostic predictor after hepatic resection, with 
higher score indicating worse prognosis [80]. Thus, among 144 patients who underwent sur-
gical resection for HCC, GPS 2 was associated with worse disease-free (HR = 2.527; 95% CI: 
1.163–5.490; p = 0.019) and overall (HR = 8.012; 95% CI: 2.818–22.784; p < 0.001) survival, but 
GPS 1 with shorter overall (HR = 2.277; 95% CI: 1.029–5.039; p = 0.042) survival than seen 
in patients preoperatively presenting with GPS 0 [80]. The independent prognostic role of 
GPS for overall survival was confirmed by other research teams [81] and meta-analysis [82]. 
Modified GPS score and dynamics of GPS score have also shown prognostic value. Thus, 
elevated modified GPS was associated with overall survival (HR = 2.21; 95% CI: 1.73–2.82; 
p < 0.05) in a meta-analysis of 2047 HCC patients [83]. Dynamics of GPS (assessed in asso-
ciation with hepatitis B infection status) was an independent predictor of overall survival in 
247 patients treated by liver resection [84]. In addition, GPS was related to blood transfusion 
requirement and postoperative pulmonary complications after liver resection for HCC [85]. 
In patients undergoing liver transplantation for HCC, elevated GPS, reaching 1 or 2, was 
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significantly associated with poor overall (p = 0.018) and recurrence-free (p = 0.030) survival. 
Complex scoring system has been created on the basis of Milan criteria and GPS [86].
Regarding advanced HCC, GPS retained independent prognostic value for survival (HR = 1.410; 
95% CI = 1.060–1.874; p = 0.018). In addition to the statistical significance of results, the biologi-
cal survival differences by GPS were also remarkable, e.g., median survival was 480 days in 
patients presenting with GPS 0 and 154 days in those having GPS 1 or 2 [87]. GPS was an inde-
pendent prognostic factor (HR = 5.483; 95% CI: 2.563–11.729; p < 0.001) for overall survival in 
patients undergoing sorafenib treatment: the median survival in those having GPS 0 versus 
elevated GPS 1 or 2 was 18.1 versus 5.2 months; p < 0.001 [88].
In HCC patients undergoing transarterial chemoembolisation, GPS was an independent prog-
nostic factor for overall survival (HR = 1.697; 95% CI: 1.325–2.174; p < 0.001). It was also found 
to be superior to other inflammation scores as NLR, PLR or modified GPS. Based on these 
findings, the authors proposed a new complex score that included Child-Pugh stage, number 
of tumour nodules and proportion of affected liver, AFP, presence or absence of portal vein 
thrombosis and GPS. The new score was also a significant predictor of survival as the HR was 
1.724; 95% CI: 1.347–2.285; p < 0.001 [89].
4. Conclusions
HCC is a frequent and aggressive malignant tumour. Longer survival can be reached in early 
diagnosed and properly treated cases. In the future, diagnosis of HCC might be based on 
combination of radiological features and miRNA profile representing liquid biopsy. MiRNA 
profile can have both diagnostic and prognostic value. Thus, further lowering of the needs for 
core biopsy might be expected, leading to patient-friendly examination and avoiding the rare 
but still possible complications. After the diagnosis of HCC has been confirmed, SIR assess-
ment by NLR and PLR represents innovative means of prognostic evaluation.
Score Definition
Glasgow prognostic score
0 C-reactive protein (CRP) < 10 mg/L AND albumin ≥35 g/L
1 One high-risk finding: CRP ≥ 10 mg/L OR albumin <35 g/L
2 Both high-risk findings: CRP ≥ 10 mg/L AND albumin <35 g/L
Modified Glasgow prognostic score
0 CRP ≤ 10 mg/L irrespective of albumin level
1 Increased CRP on the background of normal albumin level: CRP > 10 mg/L AND 
albumin ≥35 g/L
2 Increased CRP and hypoalbuminaemia: CRP > 10 mg/L AND albumin <35 g/L
Table 1. Glasgow prognostic score and its modifications [30].
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